Currently, patients with locally advanced and unresectable or metastatic NSCLC with no activating genetic abnormalities (EGFR, ALK or ROS1) should be offered immunotherapy as monotherapy or combined with chemotherapy as a standard approach [2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.